SS-31 (Elamipretide) Dosage Guide

Evidence-based protocols for the mitochondria-targeted tetrapeptide — cardiolipin stabilization, clinical trial data, Barth syndrome research, stacking with MOTS-c, cycling, and safety.

Compiled by PeptideWiki Editorial Team·Last reviewed February 24, 2026

A leading innovator in research chemicals.

All products HPLC tested

|Exclusive Offer

Coupon

10%

Off

Use our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.

Shop Now

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

Research Peptides

SS-31

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

What Is SS-31 (Elamipretide)?

SS-31 (Elamipretide, Bendavia, MTP-131) is a synthetic mitochondria-targeted tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyltyrosine — an unusual amino acid that is critical for its mitochondrial targeting properties. It was developed by Hazel Szeto and Peter Bhatt at Weill Cornell Medical College and has since advanced through multiple Phase II and Phase III clinical trials, making it one of the most clinically studied research peptides.

What makes SS-31 unique is its ability to selectively concentrate in the inner mitochondrial membrane (IMM) at concentrations over 1,000-fold higher than in the cytoplasm. Once there, it binds cardiolipin — a phospholipid found almost exclusively in the IMM that is critical for electron transport chain (ETC) function. By stabilizing cardiolipin-cytochrome c interactions, SS-31 optimizes electron flow across the ETC, reduces reactive oxygen species (ROS) production at the source, prevents cytochrome c peroxidase activity, restores mitochondrial cristae structure, and improves ATP production.

Unlike conventional antioxidants that scavenge free radicals after they are produced, SS-31 prevents excessive ROS generation at its origin — the electron transport chain itself. This “upstream” approach to mitochondrial protection is fundamentally different from and more targeted than systemic antioxidant supplementation. The compound has been studied in Barth syndrome (a genetic mitochondrial disease), heart failure, age-related macular degeneration (AMD), renal ischemia-reperfusion injury, skeletal muscle aging, and general aging/longevity contexts.

Use our Peptide Dosage to calculate your exact dose based on vial size and concentration.

Dosing information in this guide is derived from clinical trials, preclinical research, and community protocols — not from approved pharmaceutical labeling.

Key Characteristics:

Mitochondria-targeted tetrapeptide — D-Arg-Dmt-Lys-Phe-NH2; selectively concentrates >1,000x in the inner mitochondrial membrane via its aromatic-cationic motif
Cardiolipin stabilization — binds cardiolipin in the IMM to optimize ETC function, reduce ROS at the source, prevent cytochrome c peroxidase activity, and restore cristae structure
Extensive clinical trial history — Phase II/III trials for Barth syndrome (MMPOWER), heart failure (TRIAGE-HF), and AMD (ReCLAIM); FDA Breakthrough Therapy Designation for Barth syndrome
Administration — subcutaneous injection (primary community route); intravenous infusion used in clinical trials
Half-life ~4 hours (SubQ) — allows for once-daily dosing in most protocols; steady-state achieved within days of consistent administration
Generally well-tolerated — clinical trial safety data shows injection site reactions, headache, and GI discomfort as the most common adverse events; no receptor desensitization risk

For a complete overview of its mechanism and research, see our full SS-31 profile. New to peptides? Start with the Beginner's Guide to Peptides.

How SS-31 Dosage Is Determined

SS-31 dosing is better supported by clinical data than the vast majority of research peptides. Multiple Phase I, II, and III clinical trials conducted by Stealth BioTherapeutics established pharmacokinetic profiles, dose-response relationships, and safety data in human subjects. The dosing information below draws primarily from this clinical evidence, supplemented by community experience with subcutaneous administration.

Phase I Pharmacokinetic Studies

Early Phase I studies in healthy volunteers established that SS-31 is rapidly absorbed following subcutaneous injection, reaching peak plasma concentrations within approximately 1–2 hours. The elimination half-life is approximately 4 hours via the subcutaneous route. Dose-proportional pharmacokinetics were observed across a range of doses, confirming predictable drug exposure. These studies established the safety and tolerability of single and multiple doses in healthy adults.

Phase II/III Clinical Trial Dosing

The MMPOWER trials for Barth syndrome used IV infusion at doses of 0.01–0.25 mg/kg/day, with the 0.25 mg/kg dose (approximately 17.5 mg for a 70 kg adult) showing the most consistent signal in functional endpoints. The TRIAGE-HF trial for heart failure used 4-hour IV infusions at doses up to 0.25 mg/kg/hr. Later studies transitioned to subcutaneous administration, with doses up to 40 mg daily in the Phase III open-label extension. This subcutaneous data is most relevant for community protocols.

Mechanism-Based Dosing Rationale

SS-31's mechanism — selective accumulation in the inner mitochondrial membrane and cardiolipin binding — means that the effective dose depends on achieving sufficient mitochondrial membrane concentrations. Preclinical studies showed that SS-31 accumulates in mitochondria in a concentration-dependent manner with saturable binding. This suggests a therapeutic window rather than a linear dose-response relationship: once cardiolipin binding sites are occupied, additional drug provides diminishing returns.

Community-Derived Protocols

Community dosing protocols for subcutaneous SS-31 typically range from 1–5 mg daily, which is substantially lower than the 40 mg used in late-phase clinical trials. This reflects practical considerations including cost, availability, and the principle of starting conservatively with a compound whose long-term effects outside clinical trial monitoring are not fully characterized. Some users titrate up to 10 mg daily based on individual response.

Strength of evidence: Moderate-to-strong. SS-31 has more Phase II/III clinical trial data than nearly any other research peptide. The mitochondrial targeting mechanism is well-characterized in both preclinical and clinical settings. However, clinical efficacy results have been mixed across indications, and the FDA has not approved the compound. Community subcutaneous dosing is extrapolated from clinical IV data and represents best-available guidance, not established therapeutic protocols.

Standard SS-31 Dosage Ranges

SS-31 is administered by subcutaneous injection, typically once daily. Unlike GHRPs, strict fasting is not required. The dosing range below reflects both clinical trial data and community-established protocols. Because SS-31 works at the mitochondrial membrane level through cardiolipin binding (not receptor agonism), there is no desensitization concern — but the principle of using the minimum effective dose still applies.

Dosage by Experience Level

Level	Dose per Injection	Frequency	Daily Total	Notes
Beginner	1–2 mg	1x daily	1–2 mg	Assess tolerance; establish baseline response over 2–4 weeks
Intermediate	2.5–5 mg	1x daily	2.5–5 mg	Standard community protocol; most common range for general mitochondrial support
Advanced / Clinical-Equivalent	5–40 mg	1x daily	5–40 mg	Approaches clinical trial dosing (40 mg SubQ in Phase III); higher cost, typically under medical supervision

Injection Timing & Administration

Once daily dosing: The ~4-hour half-life and mitochondrial accumulation properties support once-daily administration for most protocols
Morning administration preferred: Most community protocols administer SS-31 in the morning for consistency and to align with peak metabolic demand
Fasting not required: Unlike GHRPs, SS-31's mechanism is not significantly affected by fed/fasted state; however, consistency in timing is recommended
Subcutaneous injection: Abdomen, thigh, or upper arm; rotate injection sites to minimize injection site reactions
Reconstitution: Use bacteriostatic water; swirl gently, never shake; store reconstituted solution at 2–8°C; use within 28 days

Clinical trial context: The 40 mg SubQ daily dose used in Phase III trials was administered under medical supervision with regular safety monitoring. Community users typically use 1–5 mg daily. If you plan to use doses approaching clinical trial levels, medical supervision and regular blood work are strongly recommended. Start low, titrate gradually, and monitor response.

Mitochondrial Peptide Comparison

Several peptides target mitochondrial function, but they work through fundamentally different mechanisms. Understanding these differences is essential for choosing the right compound — or for building a synergistic mitochondrial support stack. SS-31 is unique in its direct, physical targeting of the inner mitochondrial membrane.

Parameter	SS-31 (Elamipretide)	MOTS-c	Humanin	CoQ10 (Reference)
Origin	Synthetic tetrapeptide	Mitochondrial-derived (mtDNA)	Mitochondrial-derived (mtDNA)	Endogenous cofactor
Primary Target	Inner mitochondrial membrane (cardiolipin)	AMPK pathway	BAX / apoptosis pathway	ETC Complex I & III
Mechanism	Cardiolipin stabilization, ETC optimization, ROS reduction	AMPK activation, glucose metabolism, insulin sensitivity	Anti-apoptotic, cytoprotective signaling	Electron carrier in ETC
Clinical Trials	Phase II/III (multiple)	Preclinical + early clinical	Preclinical	Extensive (supplement)
Administration	SubQ injection / IV	SubQ injection	SubQ injection	Oral supplement
Synergy with SS-31	—	High (complementary mechanisms)	Moderate (different targets)	High (supports ETC function)
Best For	Mitochondrial structure/bioenergetics	Metabolic health, exercise mimetic	Neuroprotection, anti-apoptosis	General ETC support

Key takeaway: SS-31 is the only peptide that directly targets and stabilizes the inner mitochondrial membrane via cardiolipin binding. It has the strongest clinical evidence base of any mitochondria-targeted peptide. MOTS-c is the most complementary pairing because it works through a completely different mechanism (AMPK activation vs. membrane stabilization). CoQ10 is a foundational supplement that supports the same ETC that SS-31 optimizes.

Calculate Your SS-31 Dose

SS-31 is supplied as a lyophilized (freeze-dried) powder, typically in 5 mg or 10 mg vials. You reconstitute it with bacteriostatic water, then draw your dose using an insulin syringe. The concentration depends on how much water you add to the vial.

Worked Example:

Vial size: 5 mg (5,000 mcg) of SS-31
Bacteriostatic water added: 2 mL
Concentration: 5,000 mcg ÷ 2 mL = 2,500 mcg per mL (2.5 mg/mL)
Target dose: 2.5 mg (2,500 mcg)
Volume to draw: 2,500 ÷ 2,500 = 1.0 mL = 100 units on an insulin syringe (full syringe)

Alternate Example (lower dose):

Vial size: 5 mg (5,000 mcg) of SS-31
Bacteriostatic water added: 1 mL
Concentration: 5,000 mcg ÷ 1 mL = 5,000 mcg per mL (5 mg/mL)
Target dose: 2 mg (2,000 mcg)
Volume to draw: 2,000 ÷ 5,000 = 0.4 mL = 40 units on an insulin syringe

Quick Reference — 5 mg Vial

Bac Water Added	Concentration	1 mg Dose	2.5 mg Dose	5 mg Dose
0.5 mL	10 mg/mL	10 units (0.1 mL)	25 units (0.25 mL)	50 units (0.5 mL)
1 mL	5 mg/mL	20 units (0.2 mL)	50 units (0.5 mL)	100 units (1.0 mL)
2 mL	2.5 mg/mL	40 units (0.4 mL)	100 units (1.0 mL)	—
2.5 mL	2 mg/mL	50 units (0.5 mL)	—	—

Skip the Math — Use Our

Enter your vial size, water volume, and desired dose — get instant calculations with zero manual math.

SS-31 Dosage by Goal

SS-31's primary mechanism — stabilizing cardiolipin and optimizing mitochondrial electron transport — has broad implications for multiple health goals. The optimal protocol varies depending on whether you are targeting general mitochondrial support, cardiovascular health, exercise performance, neuroprotection, or age-related decline.

General Mitochondrial Support & Longevity

For users seeking to optimize mitochondrial function, protect against age-related mitochondrial decline, and support overall cellular energy production. This is the most common community use case. Conservative dosing is appropriate because SS-31's benefits are structural and cumulative, not acute.

Dose: 1–5 mg SubQ once daily
Frequency: Once daily, morning preferred
Cycle: 4–8 weeks on, 2–4 weeks off (or extended use with periodic breaks)
Stack: + CoQ10 (200–400 mg/day oral) + NAD+ precursor (NMN/NR) for comprehensive mitochondrial support

Cardiovascular & Heart Failure Support

Cardiac tissue is among the most mitochondria-dense in the body. SS-31 has been specifically studied for heart failure (TRIAGE-HF trial) and shows cardioprotective effects in preclinical models of ischemia-reperfusion injury. Higher dosing, closer to clinical trial protocols, may be appropriate under medical supervision.

Dose: 5–20 mg SubQ once daily
Frequency: Once daily
Cycle: 8–12 weeks on, 4 weeks off; or as directed by a physician
Clinical reference: TRIAGE-HF used IV doses up to 0.25 mg/kg/hr over 4-hour infusions
Note: Cardiovascular conditions require medical supervision. SS-31 is not a substitute for standard-of-care cardiac treatment.

Exercise Performance & Skeletal Muscle Aging

Preclinical research demonstrates that SS-31 improves skeletal muscle mitochondrial function and exercise tolerance, particularly in aged models. It has shown improvements in mitochondrial ATP production, reduced exercise-induced oxidative damage, and enhanced muscle energetics. Community users targeting exercise performance typically combine SS-31 with MOTS-c for synergistic metabolic and mitochondrial benefits.

Dose: 2.5–5 mg SubQ once daily
Frequency: Once daily, morning or pre-exercise (1–2 hours before training)
Cycle: 6–8 weeks on, 2–4 weeks off
Stack: + MOTS-c (5–10 mg 3–5x/week) for complementary AMPK activation and mitochondrial synergy

Neuroprotection & Cognitive Support

Neurons are highly dependent on mitochondrial function due to their extreme energy demands. Preclinical SS-31 research has demonstrated neuroprotective effects in models of neurodegenerative disease, traumatic brain injury, and age-related cognitive decline. SS-31 crosses the blood-brain barrier and accumulates in neuronal mitochondria.

Dose: 1–5 mg SubQ once daily
Frequency: Once daily
Cycle: 8–12 weeks on, 4 weeks off
Stack: Consider combining with other neuroprotective agents; Dihexa or Semax target complementary neuroprotective pathways

Renal & Organ Protection

SS-31 has shown significant renal protective effects in preclinical models of ischemia-reperfusion injury. It reduces mitochondrial damage, preserves renal tubular function, and decreases inflammatory markers. This application is most relevant for clinical or research settings, particularly peri-surgical or transplant contexts.

Dose: 5–20 mg SubQ once daily (clinical-level dosing)
Frequency: Once daily, ideally starting before the ischemic event in clinical settings
Cycle: Acute use (days to weeks) in clinical/research contexts
Note: This application is firmly in the clinical research domain; medical supervision is essential

Start conservative, titrate based on response. SS-31's benefits are structural and cumulative — they develop over weeks, not hours. Begin at the lower end of the dosing range for your goal, run a full cycle, and evaluate before increasing. The compound does not cause receptor desensitization, so there is no pharmacological reason to escalate rapidly.

Cycling & Duration

Unlike GHRPs (such as Hexarelin or GHRP-2), SS-31 does not cause receptor desensitization. Its mechanism — direct cardiolipin binding in the inner mitochondrial membrane — is not receptor-mediated in the traditional sense. This means the pharmacological rationale for cycling is different: cycling SS-31 is primarily about cost management, allowing the body to consolidate mitochondrial improvements, and maintaining caution with a compound that lacks long-term safety data outside clinical trials.

No receptor desensitization: SS-31 works by physically binding cardiolipin in the mitochondrial membrane, not by activating cell-surface receptors. Clinical trials administered it for up to 168 weeks continuously in the Barth syndrome open-label extension. Cycling is recommended for community use but is not driven by the same desensitization concerns that apply to GHRPs.

Cycling Protocols

Protocol	On-Cycle	Off-Cycle	Notes
Standard	4–8 weeks	2–4 weeks off	Most common community approach; sufficient for general mitochondrial support
Extended	8–12 weeks	4 weeks off	For cardiovascular or chronic mitochondrial support goals; closer to clinical trial durations
Chronic Support	12+ weeks	Periodic breaks (1–2 weeks every 3 months)	Informed by clinical trial data (168-week open-label extension); medical supervision recommended
Acute / Protective	1–2 weeks	As needed	Short-term use around surgical procedures or acute ischemic events; clinical/research context only

Why Off-Cycles Are Still Recommended

Even though SS-31 does not cause desensitization, periodic breaks serve several purposes for community users:

Safety margin: Long-term effects of SS-31 outside of clinical trial monitoring are not fully characterized. Periodic breaks provide a safety buffer.
Assessment window: Off-cycles allow you to evaluate whether mitochondrial improvements are sustained without continuous administration, helping determine the minimum effective protocol.
Cost management: SS-31 is among the more expensive research peptides due to its unusual amino acid (Dmt). Cycling reduces total compound usage.
Physiological consolidation: Mitochondrial biogenesis and structural remodeling are ongoing biological processes. Off-periods allow the body to consolidate improvements made during the on-cycle.

Clinical trial context: The 168-week continuous administration in the Barth syndrome open-label extension was conducted under rigorous medical supervision with regular safety monitoring including blood work, cardiac imaging, and adverse event tracking. Community users do not have this level of oversight. Err on the side of shorter cycles with breaks unless you are working with a physician who is monitoring your health.

SS-31 Stacking Protocols

SS-31 stacking focuses on complementary mitochondrial support: pairing SS-31's inner membrane cardiolipin stabilization with compounds that support other aspects of mitochondrial and cellular function. The goal is to optimize the entire mitochondrial pathway — from membrane structure (SS-31) to metabolic signaling (MOTS-c) to ETC cofactors (CoQ10, NAD+) to tissue repair (BPC-157).

SS-31 + MOTS-c — The Mitochondrial Synergy Stack

The most logical SS-31 stack. SS-31 stabilizes cardiolipin and optimizes electron transport chain function at the membrane level, while MOTS-c activates AMPK to improve glucose metabolism, insulin sensitivity, and mitochondrial biogenesis. These are completely non-overlapping mechanisms that address mitochondrial health from two different directions — structural (SS-31) and metabolic signaling (MOTS-c).

Compound	Dose	Frequency	Purpose
SS-31	2.5–5 mg SubQ	1x daily	Cardiolipin stabilization, ETC optimization, ROS reduction
MOTS-c	5–10 mg SubQ	3–5x per week	AMPK activation, glucose metabolism, mitochondrial biogenesis

Why this combination works: SS-31 ensures the mitochondrial machinery (ETC complexes, cristae structure) is functioning optimally, while MOTS-c stimulates the cell to build more mitochondria and improve metabolic substrate utilization. Together they address both the quality and quantity of mitochondrial function.

SS-31 + NAD+ Precursors + CoQ10 — Comprehensive ETC Support

A supplement-enhanced stack that provides SS-31's mitochondrial membrane optimization alongside the essential cofactors that the electron transport chain requires to function. CoQ10 serves as the primary electron carrier between Complex I/II and Complex III, while NAD+ is the central electron carrier for cellular metabolism. Both decline with age, making supplementation synergistic with SS-31's ETC optimization.

Compound	Dose	Frequency	Purpose
SS-31	2.5–5 mg SubQ	1x daily	Cardiolipin stabilization, ETC membrane optimization
CoQ10 (Ubiquinol)	200–400 mg oral	1x daily with fat-containing meal	ETC electron carrier (Complex I/II → Complex III)
NMN or NR (NAD+ precursor)	250–500 mg oral	1x daily, morning	Restores NAD+ levels for cellular metabolism and ETC function

SS-31 + BPC-157 — Mitochondrial Protection + Tissue Repair

Combines SS-31's mitochondrial-level protection with BPC-157's broad tissue repair and anti-inflammatory properties. This stack is particularly relevant for recovery from injury or surgery, where both mitochondrial stress (from ischemia-reperfusion) and tissue damage occur simultaneously. BPC-157 has also shown protective effects on mitochondrial function in preclinical models, suggesting mechanistic overlap.

Compound	Dose	Frequency	Purpose
SS-31	2.5–5 mg SubQ	1x daily	Mitochondrial protection, ETC optimization, anti-oxidative
BPC-157	250–500 mcg SubQ	1–2x daily	Tissue repair, angiogenesis, anti-inflammatory, growth factor modulation

Full Mitochondrial Optimization Stack

The comprehensive approach for users prioritizing mitochondrial health as their primary goal. Combines SS-31's membrane-level optimization with MOTS-c's metabolic signaling and essential mitochondrial cofactors. This is the most complete mitochondria-targeted protocol available.

Compound	Dose	Frequency	Purpose
SS-31	2.5–5 mg SubQ	1x daily	IMM cardiolipin stabilization, ETC optimization
MOTS-c	5–10 mg SubQ	3–5x per week	AMPK activation, mitochondrial biogenesis
CoQ10 (Ubiquinol)	200–400 mg oral	Daily	ETC electron carrier support
NMN or NR	250–500 mg oral	Daily	NAD+ restoration

Stack complexity notice: Multi-compound protocols increase both cost and the difficulty of attributing effects to individual components. If you are new to SS-31, start with SS-31 alone for at least one full cycle to establish a baseline response before adding additional compounds. This allows you to identify what SS-31 specifically contributes to your protocol.

Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.

Safety, Side Effects & Contraindications

Safety Profile: SS-31/Elamipretide has a relatively robust clinical trial safety database compared to most research peptides. Multiple Phase II and III trials involving hundreds of patients have characterized its adverse event profile. Generally well-tolerated, with injection site reactions being the most common complaint. However, it is NOT FDA-approved, and long-term safety data outside clinical trial monitoring is limited.

Common Side Effects

From clinical trial data — generally mild and manageable:

Injection site reactions — redness, pain, swelling, or induration at the SubQ injection site; the most frequently reported adverse event across clinical trials
Headache — reported in a subset of trial participants; typically mild and transient
Gastrointestinal discomfort — nausea, abdominal pain, or diarrhea; reported at low frequency in clinical trials
Fatigue — occasional reports, usually in the first days of administration
Dizziness — infrequent; more commonly reported with IV administration than SubQ

Less common / clinical trial observations:

Upper respiratory tract infection — reported in long-term extension studies (may not be causally related)
Musculoskeletal pain — occasional reports; relationship to treatment uncertain
Contact urticaria — skin reaction at injection site; reported in some patients

No desensitization or hormonal disruption: Unlike GHRPs, SS-31 does not stimulate GH, cortisol, or prolactin release. It does not affect hormonal axes. There are no reports of receptor desensitization with continued use. This makes its side effect profile fundamentally different from — and generally cleaner than — growth hormone secretagogues like Hexarelin or GHRP-2.

Contraindications

Known hypersensitivity — to SS-31/Elamipretide or any of its components, including the unusual amino acid Dmt (2',6'-dimethyltyrosine). Discontinue immediately if allergic reaction occurs.
Pregnancy and breastfeeding — no safety data exists for SS-31 during pregnancy or nursing. The effects of a mitochondria-targeted compound on fetal development are unknown. Avoid entirely.
Active cancer — while SS-31's mechanism is distinct from growth factor stimulation, improved mitochondrial function could theoretically support the metabolic demands of rapidly dividing cells. Avoid use with active malignancies until more data is available.
Severe hepatic or renal impairment — SS-31 elimination pathways have not been fully characterized in patients with severe organ dysfunction. Use with caution and medical supervision.
Concurrent use of mitochondrial toxins — certain medications (e.g., some antibiotics, chemotherapy agents) are known mitochondrial toxins. The interaction between SS-31's mitochondrial protection and these agents is not well studied. Consult a physician.

When to Stop or Reduce Dose

Significant injection site reactions that do not resolve between doses (persistent induration, pain, or spreading erythema)
Persistent GI symptoms (nausea, abdominal pain) that interfere with daily functioning
Any signs of allergic reaction (rash, urticaria, difficulty breathing, facial swelling) — discontinue immediately and seek medical attention
Unexplained fatigue or malaise that develops or worsens during administration
Any symptom that feels unusual or concerning — err on the side of caution with any research compound

Regulatory Status: SS-31/Elamipretide is NOT FDA-approved for any indication. It received Breakthrough Therapy Designation for Barth syndrome, but the FDA issued a Complete Response Letter (CRL) in 2021 requesting additional data. The compound remains in clinical development by Stealth BioTherapeutics. It is classified as a research peptide and is not approved for human therapeutic use. Regulations vary by jurisdiction — verify your local laws before purchasing.

Common SS-31 Dosing Mistakes

Avoid these common errors to get the most out of your SS-31 protocol:

Expecting immediate results from a structural-level intervention: SS-31 works by restoring mitochondrial membrane structure and electron transport chain efficiency. This is not a stimulant — benefits develop over weeks as mitochondrial function improves. Clinical trials measured outcomes at 12–28 weeks. Allow at least 4–8 weeks before evaluating effectiveness.

Using doses far above clinical trial ranges without justification: Clinical trials used carefully titrated doses (0.01–0.25 mg/kg IV or up to 40 mg SubQ). Community doses of 1–5 mg daily are reasonable extrapolations, but dramatically exceeding these ranges does not have supporting evidence and increases risk. More is not necessarily better with a compound that works at the mitochondrial membrane level.

Confusing SS-31 with a growth hormone secretagogue or performance enhancer: SS-31 is a mitochondria-targeted peptide that works by stabilizing cardiolipin and optimizing electron transport. It does not stimulate GH release, activate ghrelin receptors, or function as an anabolic agent. Its benefits are in cellular energy production, mitochondrial health, and protection against oxidative damage — not acute performance enhancement.

Poor reconstitution and storage practices: SS-31 is supplied as a lyophilized powder that must be reconstituted with bacteriostatic water and stored properly. Use gentle swirling (never shake) when reconstituting. Store reconstituted solution refrigerated at 2–8°C and use within 28 days. Freeze-thaw cycles and improper storage degrade the peptide.

Not stacking with complementary mitochondrial support: SS-31 optimizes electron transport chain efficiency, but the ETC requires adequate cofactors to function. CoQ10, NAD+ precursors (NMN/NR), and adequate B vitamins are all important for the mitochondrial pathways that SS-31 enhances. Using SS-31 without basic mitochondrial cofactor support is suboptimal.

Using SS-31 as a substitute for addressing root causes of mitochondrial dysfunction: SS-31 can protect and restore mitochondrial function, but it does not address underlying causes like chronic inflammation, nutrient deficiencies, metabolic syndrome, or sedentary behavior. Sleep, exercise, and a nutrient-dense diet remain the foundation of mitochondrial health. SS-31 should supplement these fundamentals, not replace them.

Assuming all research peptide sources provide authentic SS-31: SS-31 contains an unusual amino acid (2’,6’-dimethyltyrosine / Dmt) that makes synthesis more complex than standard peptides. This increases the likelihood of impure or mislabeled product from low-quality sources. Third-party testing (HPLC purity, mass spectrometry identity confirmation) is particularly important for this peptide.

Ignoring the clinical trial evidence base: SS-31 is one of the few research peptides with extensive Phase II/III clinical trial data. Ignoring this data and relying solely on anecdotal community reports means missing important information about effective doses, timelines, and realistic expectations. The clinical literature should be your primary reference point for this compound.

Frequently Asked Questions

Key Takeaways

SS-31 is a mitochondria-targeted tetrapeptide — it selectively concentrates >1,000x in the inner mitochondrial membrane and stabilizes cardiolipin to optimize electron transport chain function
Community dosing: 1–5 mg SubQ once daily — clinical trials used up to 40 mg SubQ daily. Start at 1–2 mg and titrate based on response and goals.
Extensive clinical trial data — Phase II/III trials for Barth syndrome (MMPOWER), heart failure (TRIAGE-HF), and AMD (ReCLAIM). FDA Breakthrough Therapy Designation for Barth syndrome, but CRL received in 2021.
No receptor desensitization — SS-31 works via direct cardiolipin binding, not receptor agonism. Cycling is recommended for safety and cost management, not because of tolerance development.
Best stack: SS-31 + MOTS-c for complementary mitochondrial support (membrane stabilization + AMPK metabolic signaling). CoQ10 and NAD+ precursors further support the ETC pathways that SS-31 optimizes.
Generally well-tolerated — injection site reactions, headache, and GI discomfort are the most common side effects in clinical trials. No hormonal disruption (unlike GHRPs).
Benefits develop over weeks, not days — SS-31 works by restoring mitochondrial structure and function. Allow 4–8 weeks for meaningful effects. This is not a stimulant.
Cycling: 4–8 weeks on, 2–4 weeks off for standard protocols. Extended use (12+ weeks) is informed by clinical trial data but should include periodic breaks for community use.
Unique amino acid (Dmt) complicates synthesis — third-party testing (HPLC, mass spectrometry) is particularly important to verify identity and purity from research peptide sources.
NOT FDA-approved — classified as a research peptide despite extensive clinical development. CRL received 2021 for Barth syndrome indication. Consult a healthcare provider before use.

This article is for educational and informational purposes only. See our Disclaimer.

References

Szeto HH. “First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.” Br J Pharmacol. 2014;171(8):2029-2050. PubMed
Birk AV, et al. “The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.” J Am Soc Nephrol. 2013;24(8):1250-1261. PubMed
Szeto HH, Birk AV. “Serendipity and the discovery of novel compounds that restore mitochondrial plasticity.” Clin Pharmacol Ther. 2014;96(6):672-683. PubMed
Reid Thompson W, et al. “A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.” Genet Med. 2021;23(3):471-478. PubMed
Butler J, et al. “Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: the PROGRESS-HF phase 2 trial.” J Card Fail. 2020;26(5):429-437. PubMed
Daubert MA, et al. “Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide.” Circ Heart Fail. 2017;10(12):e004389. PubMed
Petri S, et al. “SS-31 peptide reverses the mitochondrial fragmentation present in fibroblasts from patients with DCMA.” Front Cell Dev Biol. 2021;9:620511.
Campbell MD, et al. “Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice.” Free Radic Biol Med. 2019;134:268-281. PubMed
Siegel MP, et al. “Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice.” Aging Cell. 2013;12(5):763-771. PubMed
Allen ME, et al. “The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae and biosynthetic constituents in mitochondria of fibroblasts from Barth syndrome patients.” Cells. 2021;10(11):3125.

Next Steps

Continue your research with these resources.

MOTS-c Dosage Guide

Learn dosing protocols for MOTS-c — the ideal complementary mitochondrial peptide for stacking with SS-31.

Read Guide

Dosage Calculator

Calculate your exact SS-31 dose based on vial size and reconstitution volume.

Open Calculator

Peptide Directory

Browse all peptides with research summaries and dosing data.

View Directory